DUBLIN, June 21, 2019 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental biologics application (sBLA) for Botox for the treatment of pediatric patients (2 to…Original Article
FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
